Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?

[1]  M. Manns,et al.  Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis , 2007, Annals of Internal Medicine.

[2]  S. Pol,et al.  Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. , 2007, World journal of gastroenterology.

[3]  Yoshiyuki Suzuki,et al.  Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. , 2007, Journal of medical virology.

[4]  H. Thomas,et al.  Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications , 2007, Journal of viral hepatitis.

[5]  Yoshiyuki Suzuki,et al.  Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C , 2007, Journal of medical virology.

[6]  J. Marrero,et al.  Viral hepatitis and hepatocellular carcinoma. , 2007, Archives of medical research.

[7]  M. Kudo,et al.  Antibody to Hepatitis B Core Antigen and Risk for Hepatitis CRelated Hepatocellular Carcinoma , 2007, Annals of Internal Medicine.

[8]  M. Tsai,et al.  Predictors of alpha‐fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a–ribavirin combination therapy , 2007, Journal of gastroenterology and hepatology.

[9]  D. Roulot,et al.  Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  M. Lai,et al.  [1] DURABLE SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT WITH PEGINTERFERON α-2a (PEGASYS®) ALONE OR IN COMBINATION WITH RlBAVlRlN (COPEGUS®): 5-YEAR FOLLOW-UP AND THE CRITERIA OF A CURE , 2007 .

[11]  A. Tamori,et al.  Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[12]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[13]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[14]  N. Ganne-Carrié,et al.  Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  J. Olynyk,et al.  Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo , 2006, Hepatology.

[16]  T. Ide,et al.  A Decrease in AFP Level Related to Administration of Interferon in Patients with Chronic Hepatitis C and a High Level of AFP , 2006, Digestive diseases and sciences.

[17]  S. Francque,et al.  Viral hepatitis and hepatocellular carcinoma , 2005, World journal of surgical oncology.

[18]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[19]  T. Liang,et al.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma. , 2004, Gastroenterology.

[20]  E. Heathcote,et al.  Prevention of hepatitis C virus-related hepatocellular carcinoma. , 2004, Gastroenterology.

[21]  A. Alberti,et al.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications , 2004, Gut.

[22]  J. Henriksen,et al.  Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. , 2004, Journal of hepatology.

[23]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[24]  M. Yuen,et al.  Viral hepatitis C , 2003, The Lancet.

[25]  H. El‐Serag,et al.  The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? , 2003, American Journal of Gastroenterology.

[26]  T. Okanoue,et al.  Hepatocellular carcinoma in sustained responders of interferon‐treated chronic hepatitis C , 2003, Journal of gastroenterology and hepatology.

[27]  K. Hanazaki,et al.  Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy , 2002, Journal of gastroenterology and hepatology.

[28]  T. Wright.  Treatment of patients with hepatitis C and cirrhosis , 2002, Hepatology.

[29]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[30]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[31]  E. Schiff,et al.  A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.

[32]  M. Zoli,et al.  Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis , 2001, Gut.

[33]  S. Hadziyannis,et al.  Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.

[34]  P. Andreone,et al.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. , 2001, Journal of hepatology.

[35]  A. Tamori,et al.  Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis , 2001, The Lancet.

[36]  A. Alberti,et al.  Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. , 1999, Hepato-gastroenterology.

[37]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[38]  G. Raimondo,et al.  Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. , 1999, The New England journal of medicine.

[39]  P. Marcellin,et al.  Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment , 1999, Hepatology.

[40]  M. Shindo,et al.  Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy , 1999, Cancer.

[41]  K. Chayama,et al.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis , 1999, Hepatology.

[42]  T. Okanoue,et al.  Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. , 1999, Journal of hepatology.

[43]  Yoshiharu Matsuura,et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.

[44]  Y. Imai,et al.  Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 1998, Annals of Internal Medicine.

[45]  T. Morizane,et al.  Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection , 1998, The Lancet.

[46]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[47]  H. Tilg.  New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. , 1997, Gastroenterology.

[48]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[49]  Ding‐Shinn Chen,et al.  Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. , 1992, Gastroenterology.